<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part2">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>2</PartID>
        <PartNumber>Part I</PartNumber>
        <PartSequenceNumber>2</PartSequenceNumber>
        <PartTitle>Hormone Therapy</PartTitle>
        <PartChapterCount>9</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap7" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>7</ChapterID>
          <ChapterNumber>Chapter 7</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_7</ChapterDOI>
          <ChapterSequenceNumber>7</ChapterSequenceNumber>
          <ChapterTitle Language="En">5-Alpha Reductase Inhibitors in Prostate Cancer</ChapterTitle>
          <ChapterFirstPage>83</ChapterFirstPage>
          <ChapterLastPage>89</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>2</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_7" CorrespondingAffiliationID="Aff1_7">
              <AuthorName DisplayOrder="Western">
                <GivenName>Zoran</GivenName>
                <FamilyName>Culig</FamilyName>
              </AuthorName>
              <Contact>
                <Email>zoran.culig@l-med.ac.at</Email>
              </Contact>
            </Author>
            <Affiliation ID="Aff1_7">
              <OrgDivision>Department of Urology</OrgDivision>
              <OrgName>Innsbruck Medical University</OrgName>
              <OrgAddress>
                <City>Innsbruck</City>
                <Country>Austria</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_7" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Androgenic effects in prostate cancer cells depend on the synthesis and metabolism of hormones and the presence of androgen receptor. 5-alpha reductase isoenzymes I and II differ in chromosomal localization, pH optimum, enzyme kinetics, and expression in benign and malignant prostate tissue. In prostate cancer tissues, there is an increased expression of the isoenzyme type I. The possibilities for pharmacological intervention include drug(s) that inhibit both isoforms such as dutasteride or extract from <Emphasis Type="Italic">Serenoa repens</Emphasis> or type II inhibitors such as finasteride. 5-alpha reductase inhibitors are used in benign prostate hyperplasia therapy, and it has been postulated that they may also be beneficial in preventive strategies for prostate cancer. Due to its dual effect on 5-alpha reductase inhibition, dutasteride may be preferred over finasteride for prostate cancer prevention. Data from large clinical studies have indicated that these inhibitors reduce the risk of prostate cancer; however, there are concerns that should be discussed. Importantly, there may be an increased number of high-grade Gleason tumors in patients treated with finasteride.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>5-alpha reductase</Keyword>
            <Keyword>Dutasteride</Keyword>
            <Keyword>Finasteride</Keyword>
            <Keyword>Izoenzyme</Keyword>
            <Keyword>Prostate cancer</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Prostate cancer (CaP) dependency on androgenic stimulation has been well known since the early work of Huggins and Hodges in the twentieth century. Therapies for advanced prostate cancer are therefore based on inhibition of androgenic stimulation but are palliative only. A number of paracrine and autocrine factors that stimulate the growth of CaP have been identified, and some novel experimental therapies have been considered in combination with antiandrogen treatment. The two most important androgenic steroids are testosterone and dihydrotestosterone (DHT). They both bind to the androgen receptor (AR). Conventional nonsteroidal antiandrogens, such as hydroxyflutamide and bicalutamide, are effective for a certain time period and cause a temporary control of tumor growth. It was shown that these two antiandrogens may act as agonists under certain conditions [<CitationRef CitationID="CR1_7">1</CitationRef>, <CitationRef CitationID="CR2_7">2</CitationRef>]. In particular, a prolonged treatment with an antiandrogen may lead to appearance of receptor mutations. If mutant ARs are stimulated by antiandrogens, one could understand that the tumor growth is paradoxically promoted by the drug. It should be kept in mind that AR expression and transcriptional activity may increase during long-term androgen ablation. The data obtained in several laboratories indicate that the inhibition of the ligand–receptor axis of AR may be reasonable in a subgroup of patients who present with a late stage tumor [<CitationRef CitationID="CR3_7">3</CitationRef>, <CitationRef CitationID="CR4_7">4</CitationRef>]. On the other hand, there is experimental evidence showing the role of the AR in maintaining differentiation function of the prostate gland. Prostate-specific antigen (PSA) is thus induced by some nonsteroidal agents such as interleukin-6, phenylbutyrate, and phenylacetate [<CitationRef CitationID="CR5_7">5</CitationRef>, <CitationRef CitationID="CR6_7">6</CitationRef>]. Current therapies cannot unfortunately distinguish between the inhibition of proliferation and differentiation mediated by the AR. In this chapter, there is a focus on therapeutic inhibition of the androgen–AR axis by interfering with production of the ligand DHT.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Androgens and Androgen Receptor</Heading>
            <Para TextBreak="No">There is a major difference between testosterone and its derivative DHT in the binding affinity for the AR. It has been shown that the binding affinity of testosterone is about one-third of that of DHT. Consequently, higher concentrations of testosterone are required to achieve the same effect. In many in vitro experiments, the synthetic androgens such as methyltrienolone (R1881) or mibolerone are used because of their low metabolic rate in comparison with natural androgens. Binding of androgens to the receptor leads to receptor translocation to the nucleus where the ligand–receptor complex is recruited onto DNA sequences of promoters of target genes. Importantly, testosterone and DHT regulate the proliferation in a biphasic manner thus stimulating cellular growth at lower concentrations. It is known that this effect is mostly mediated through stimulation of cyclin-dependent kinases and cyclins [<CitationRef CitationID="CR7_7">7</CitationRef>]. At higher androgen concentrations, the inhibitors of cell cycle such as p27 or p21 are induced. There is a growing body of evidence clearly showing that AR-associated coactivators are required for optimal action of androgens. The knowledge on coactivators whose expression has increased in prostate cancer is being improved recently. It is, however, not known whether there are preferential coactivators for DHT and testosterone in benign and malignant prostate cells. Some of the coactivators are being considered targets for therapy because of their high expression in CaP and promotion of agonistic activities of antiandrogens and stimulation of proliferation and migration [<CitationRef CitationID="CR8_7">8</CitationRef>, <CitationRef CitationID="CR9_7">9</CitationRef>]. Interestingly, it was shown that the transcriptional integrator p300 may even replace the AR in induction of expression of specific genes in prostate cancer cells [<CitationRef CitationID="CR10_7">10</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec3">
            <Heading>Conversion of Testosterone to DHT: 5-Alpha Reductase</Heading>
            <Para TextBreak="No">The 5-alpha reductase enzyme, which is membrane-associated and NAPDH-dependent, exists in two isoforms in the human body: type I (SRD5A1), which is expressed in the liver and skin, and type II (SRD5A2), which is predominant in the prostate [<CitationRef CitationID="CR11_7">11</CitationRef>]. Chromosomal localization of these two isoforms differs; while the gene encoding the type I 5-alpha reductase is located on chromosome 5, the gene for the 5-alpha reductase II is situated on chromosome 2. The two isoforms do have a dissimilar homology and enzyme kinetics. The pH optimum for the isoenzyme I is between 6 and 8 and for the isoenzyme II between 5 and 6. The type II isoform has a higher affinity for testosterone than the type I isoform. 5-alpha reductase type I requires a higher steroid substrate concentration to achieve a half maximal rate of DHT production.</Para>
            <Para TextBreak="No">In the organs of the genitourinary system, the 5-alpha reductase I isoenzyme is expressed in preputial skin, whereas stromal cells in the seminal vesicle are type II-positive. A clinical syndrome of 5-alpha reductase deficiency is not associated with the type I isoenzyme. A genetic mutation of the type II 5-alpha reductase was discovered in a male population of the Dominican Republic [<CitationRef CitationID="CR12_7">12</CitationRef>]. Due to this somatic mutation, affected subjects present with ambiguous genitalia at birth and rudimentary prostate. Partial virilization is sometimes observed in males during puberty because of an increased expression of the type I enzyme. Defects in virilization were also reported in male monkeys that were treated with an inhibitor of type II 5-alpha reductase. In individuals with 5-alpha reductase II mutations, there is no development of benign prostate hyperplasia (BPH) or prostate cancer. In the prostate gland, 5-alpha reductase type II was detected in both epithelial and stromal cells.</Para>
          </Section1>
          <Section1 ID="Sec4">
            <Heading>The Role of 5-Alpha Reductase in the Nonmalignant Disease of the Prostate</Heading>
            <Para TextBreak="No">Androgens regulate vasculogenesis in both benign and malignant prostate tissue. The underlying mechanism involves upregulation of vascular endothelial growth factor [<CitationRef CitationID="CR13_7">13</CitationRef>]. Since BPH is characterized by increased blood flow, the inhibitors of 5-alpha reductase may provide some relief in this disorder. In addition, the inhibitors of 5-alpha reductase could be used for prophylaxis of BPH complications. However, it is generally accepted that these drugs should not be used in individuals who have severe BPH symptoms [<CitationRef CitationID="CR14_7">14</CitationRef>]. If the medication is discontinued, the symptoms usually reappear.</Para>
          </Section1>
          <Section1 ID="Sec5">
            <Heading>5-Alpha Reductase and Cancer</Heading>
            <Para TextBreak="No">With the development of specific anti-5-alpha reductase antibodies, it has become possible to perform isotype-specific immunohistochemical and Western blot analyses. In general, these studies yielded the consensus that the relationship between the enzyme isoforms I and II may change in prostate tumor development and carcinogenesis. Moreover, it was confirmed by steroid 5-alpha reductase in vitro assays that the activity of 5-alpha reductase I increases in prostate cancer [<CitationRef CitationID="CR15_7">15</CitationRef>]. Thus, the isoform I may become, for reasons which are not completely clear, the predominant isoform in high-grade prostate intraepithelial neoplasia and malignancy. It has been speculated that under conditions in which the hypoxia-inducible factor 1 alpha is elevated, the promoter of carboanhydrase 9, a tumor-associated transmembrane enzyme that influences intracellular pH towards increased activity of the isoenzyme type I, becomes more active. Since Mohler’s group demonstrated that the intraprostatic androgens are present at sufficient levels to stimulate growth of recurrent tumors, the presence of the 5-alpha reductase in clinical specimens is clinically relevant [<CitationRef CitationID="CR16_7">16</CitationRef>]. Testosterone levels of 3.75 pmol/g tissue were measured in recurrent tumors, whereas its content in androgen-stimulated benign prostate was 2.75 pmol/g. When 5-alpha reductase was compared between different grades of localized prostate tumors by immunohistochemistry, it was shown, however, that there is an increase of either 5-alpha reductase isoenzyme with a higher Gleason grade [<CitationRef CitationID="CR17_7">17</CitationRef>]. It is also interesting that Habib and associates reported the loss of both 5-alpha reductase isoforms in metastatic lymph node and bone lesions of CaP [<CitationRef CitationID="CR18_7">18</CitationRef>]. This finding is important and undoubtedly leads to some novel questions related to the generation of androgens in the metastatic lesions of CaP. In prostate cancer, there is either the presence of AR in metastatic lesions or its absence due to epigenetic changes in the promoter of the gene [<CitationRef CitationID="CR19_7">19</CitationRef>, <CitationRef CitationID="CR20_7">20</CitationRef>].</Para>
            <Para TextBreak="No">Somatic 5-alpha reductase mutations may occur in prostate cancer tissue. Makriadis and associates reported that such mutations could be detected in about two third of CaP patients [<CitationRef CitationID="CR21_7">21</CitationRef>]. These mutations may lead to either increased or decreased activity of the enzyme, or they may not change its activity. The mutations with increased 5-alpha reductase activity appear to be more common than those with an opposite effect. The presence of 5-alpha reductase mutations should be taken into consideration when discussing the responsiveness of individual patients to therapy with 5-alpha reductase inhibitors. Most mutations of the coding region of the 5-alpha reductase gene occurred early in prostate cancer development. A49T mutation of the 5-alpha reductase gene has increased the risk of African-American men by 7.2-fold and of men of Hispanic origin in Los Angeles by 3.6-fold [<CitationRef CitationID="CR22_7">22</CitationRef>]. The higher risk may be due to an increased conversion of testosterone into DHT.</Para>
          </Section1>
          <Section1 ID="Sec6">
            <Heading>5-Alpha Reductase Inhibitors</Heading>
            <Para TextBreak="No">5-alpha reductase inhibitors lead, in general, to inhibition of DHT serum concentration, whereas the testosterone serum levels are elevated. Intraprostatic levels of DHT, however, remain significantly lower after treatment with an 5-alpha reductase inhibitor. Pharmacological inhibitors of 5-alpha reductase discussed in the chapter are finasteride and dutasteride. There is no specific 5-alpha reductase type I isoform inhibitor available in the market. The first compound is a product of Merck that was developed earlier and inhibits the type II isoform. Several years after the development of finasteride, GlaxoSmithKline developed dutasteride, a drug that inhibits both enzyme isoforms and causes a stronger inhibition of intraprostatic DHT expression. Dutasteride is approved at a dosage of 0.5 mg/day orally for the treatment of BPH. A higher percentage of primary cultures of prostate cancer cells was inhibited by dutasteride than finasteride [<CitationRef CitationID="CR23_7">23</CitationRef>]. Dutasteride was found to exert a more potent effect on the H rat prostate Dunning tumor that contains increased levels of the type I enzyme. In preclinical research with LNCaP xenografts, the effects of finasteride and dutasteride were compared by Xu and associates [<CitationRef CitationID="CR24_7">24</CitationRef>]. They reported a double advantage for dutasteride, causing an inhibition of xenograft growth that is more effective than that caused by castration alone. The effect of dutasteride was also more pronounced than that of finasteride. Dutasteride has been also identified as a molecule that inhibits enzyme fatty acid synthase that is overexpressed in CaP and correlates with a poor prognosis. The genes involved in metabolism and catalytic activity are strongly influenced by treatment with dutasteride in vitro [<CitationRef CitationID="CR25_7">25</CitationRef>]. Dutasteride also upregulated the expression of caspases 3 and 7 and genes involved in the pro-apoptotic pathway of FasL/tumor necrosis factor alpha. Thus, experimental data have indicated that dual 5-alpha reductase inhibitor(s) may be more appropriate for prevention and/or therapy than a single type inhibitor. Since the treatment with dutasteride will not eliminate all androgenic actions in prostate cancer, the addition of an antiandrogen to a therapy regimen may be appropriate. Finasteride, in combination with intermittent androgen withdrawal, improved survival of mice bearing LNCaP tumor [<CitationRef CitationID="CR26_7">26</CitationRef>]. On the other hand, it was found that finasteride has a favorable effect on the Bcl-2/Bax ratio and also decreases Bcl-x. The same authors showed that finasteride increases the effect on caspase 3, thus confirming induction of apoptosis. In other studies, it was reported that finasteride may prevent the progression of rat prostate cancer to macroscopic disease [<CitationRef CitationID="CR27_7">27</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec7">
            <Heading>Clinical Studies with 5-Alpha Reductase Inhibitors in Prostate Cancer</Heading>
            <Para TextBreak="No">Different study endpoints have been considered in clinical studies with 5-alpha reductase inhibitors. Some investigators follow a decrease in serum PSA parameters. This section focuses on the proposed role of finasteride in prevention of prostate cancer and discusses the reasons for the controversial findings reported. In an early clinical study, finasteride treatment over 6 weeks was associated with a decrease in PSA in individuals who did not present with a positive bone scan [<CitationRef CitationID="CR28_7">28</CitationRef>]. Similar findings were obtained in another study in which the most notable response was that of PSA [<CitationRef CitationID="CR29_7">29</CitationRef>]. However, it should be kept in mind that PSA is not a useful endpoint for a study with finasteride since it is known that finasteride itself has a negative regulatory effect on PSA. Finasteride inhibits complex formation between steroid receptor-binding consensus and nuclear proteins as a consequence of AR expression inhibition [<CitationRef CitationID="CR30_7">30</CitationRef>]. In this context, it is worthwhile to note that the phytotherapeutic agent <Emphasis Type="Italic">Serenoa repens</Emphasis> has an effect on 5-alpha reductase inhibition in the growth of prostate cancer cell lines without affecting PSA protein expression [<CitationRef CitationID="CR31_7">31</CitationRef>]. Thus, <Emphasis Type="Italic">Serenoa repens</Emphasis>, a dual 5-alpha reductase inhibitor, does not interfere with expression or transcriptional activity of the AR. Prostate cancer cells treated with <Emphasis Type="Italic">Serenoa repens</Emphasis> show accumulation of lipids in the cytoplasm and damage of mitochondrial and nuclear membranes. However, it should be pointed out that the strong effects of <Emphasis Type="Italic">Serenoa repens</Emphasis> were not observed by all researchers and may be cell context-dependent. In addition to inhibition of 5-alpha reductase, alternative mechanisms such as anti-inflammatory action by which <Emphasis Type="Italic">Serenoa repens</Emphasis> inhibits tumor growth are being discussed.</Para>
            <Para TextBreak="No">In much larger studies, such as Prostate Cancer Prevention Trial (PCPT) study, medical therapy of prostate symptoms (MTOPS), and the phase IIIa program for dutasteride, the focus was on (a) treatment of BPH and (b) prevention of cancer development (Table <InternalRef RefID="Tab1">7.1</InternalRef>). Male individuals with high levels of PSA (&gt;10 ng/ml) were excluded from the studies because of the likelihood of the presence of prostate cancer. At present, it is rather difficult to distinguish between clinically indolent and significant cancers detected in large prevention studies, especially if the Gleason score is intermediate. Considerable effort has been taken to better distinguish between these two groups on the basis of genomic and proteomic analyses; however, there are remarkable differences between the results reported from different centers.<Table Float="Yes" ID="Tab1">
                <Caption Language="En">
                  <CaptionNumber>Table 7.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Large clinical studies with 5-alpha reductase inhibitors in prostate diseases</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="5">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <colspec colname="c3" colnum="3"/>
                  <colspec colname="c4" colnum="4"/>
                  <colspec colname="c5" colnum="5"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Study</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Number of subjects</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>End of the study</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Effect on cancer incidence</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Higher gleason score</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>PCPT</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>1,300</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Yes</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Yes</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Yes</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>MTOPS</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>18,882</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Yes</SimplePara>
                      </entry>
                      <entry colname="c4"/>
                      <entry colname="c5"/>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>IIIa for dutasteride</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>1,908</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Yes</SimplePara>
                      </entry>
                      <entry colname="c4"/>
                      <entry colname="c5"/>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Reduce</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>8,000</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>No</SimplePara>
                      </entry>
                      <entry colname="c4"/>
                      <entry colname="c5"/>
                    </row>
                  </tbody>
                </tgroup>
              </Table>
            </Para>
            <Para TextBreak="No">In the MTOPS study, which was designed to assess the effects of finasteride alone or in combination with the blocker of alpha 1-adrenoreceptor doxazosine, more than 1,300 men participated [<CitationRef CitationID="CR32_7">32</CitationRef>]. It was evident that the percentage of prostate cancer-positive biopsies decreased in patients who were treated with finasteride. It was found that finasteride treatment had provided beneficial effects on BPH symptoms. One of the issues that cause controversies in discussions on the impact of finasteride treatment for prostate cancer is an increasing number of tumors detected with a higher Gleason score (i.e., 7–10) [<CitationRef CitationID="CR33_7">33</CitationRef>]. In the dutasteride study, there was no evidence for increased risk of high Gleason score cancer following inhibition of 5-alpha reductase. There is a concern that most studies cited in this paragraph are more relevant to BPH rather than cancer biology, and the results regarding cancer histology could not be accepted with confidence.</Para>
            <Para TextBreak="No">The largest number of patients (<Emphasis Type="Italic">n</Emphasis> = 18,882 subjects) in a single study was recruited in the PCPT study performed between 1994 and 2004 [<CitationRef CitationID="CR34_7">34</CitationRef>]. The study subjects had normal digital rectal examination and serum PSA level lower than 3 ng/ml. The patients were randomized to take either finasteride or placebo. The difference in the cancer prevalence between 24.4% (placebo group) and 18.4% (finasteride group) was found to be statistically significant. Considering the clinical stage, most of the tumors detected in the study were T1 and T2. In the finasteride group, most tumors were less likely to be bilateral. At the same time, the percentage of high Gleason score tumors (7–10) was 37% after finasteride treatment in contrast to 22% in the placebo group. However, the validity of these results was questioned because of a fewer number of biopsies performed in the group of patients who received finasteride. Other arguments against the causative role of finasteride include the lack of divergence over time, increase in PSA levels in patients receiving placebo only, and lack of assessment of prostate cancer status in men treated with finasteride. An “effect” of finasteride on the increase in the percentage of high-grade tumors might, in fact, be masked by a decrease in the percentage of low-grade tumors. For the REDUCE trial, 8,000 individuals with increased risk of prostate cancer development have been selected on the basis of clinical evaluation and biopsy [<CitationRef CitationID="CR35_7">35</CitationRef>]. The running time of the REDUCE study is 4 years, and the study is international, multicentered, randomized, double-blinded, and placebo-controlled.</Para>
            <Para TextBreak="No">Both finasteride and dutasteride have an impact on reduction of prostate volume. Thus, the detection of prostate cancer may, in fact, increase since the tumors might be easily diagnosed due to a smaller volume of the prostate [<CitationRef CitationID="CR36_7">36</CitationRef>]. Dutasteride was applied in combination with bicalutamide prior to brachytherapy, and it was show to display an inhibitory effect on prostate volume comparable to that caused by luteinizing hormone-releasing hormone [<CitationRef CitationID="CR37_7">37</CitationRef>].</Para>
            <Para TextBreak="No">Histologically, the effects of 5-alpha reductase inhibitors in prostate caused changes similar to those caused by androgen ablation therapy [<CitationRef CitationID="CR38_7">38</CitationRef>]. However, they were milder compared to those caused by androgen withdrawal. Signs of atrophy and involution, existence of smaller nuclei and nucleoli, increased apoptosis, and reduced density of microvessels were seen. There is a consensus that Gleason grading could, therefore, not be appropriately determined after prostate cancer treatment, with either anti-androgens or 5-alpha reductase inhibitors. At present, there are several novel molecules proposed to be used as markers for prostate cancer. They may be used in further studies with finasteride as well.</Para>
            <Para TextBreak="No">Some additional effects of finasteride treatment in prostate cancer may include impaired sexual function in these men, and in rare cases, disturbances such as depression or neurotoxicity.</Para>
            <Para TextBreak="No">In summary, although there is some clinical evidence supporting the use of 5-alpha reductase inhibitors in prostate cancer prevention, several additional studies seem to be justified. Further studies may be designed also with the aim of including information on the preventive effects of finasteride or dutasteride in ethnic groups with different levels of prostate cancer risk. The effectiveness of finasteride or dutasteride may be compared with that of some other agents being currently used such as selenium or resveratrol.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_7.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_7">
              <CitationNumber>1.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Veldscholte</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Ris-Stalpers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GG</Initials>
                  <FamilyName>Kuiper</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Jenster</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Berrevoets</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Claassen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HC</Initials>
                  <FamilyName>Rooij</FamilyName>
                  <Particle>van</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Trapman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AO</Initials>
                  <FamilyName>Brinkmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Mulder</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens</ArticleTitle>
                <JournalTitle>Biochem Biophys Res Commun</JournalTitle>
                <VolumeID>173</VolumeID>
                <FirstPage>534</FirstPage>
                <LastPage>40</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0006-291X(05)80067-1</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1998;173:534–40.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_7">
              <CitationNumber>2.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Hara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Miyazaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Araki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Yamaoka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Kanzaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kusaka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Miyamoto</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>63</VolumeID>
                <FirstPage>149</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>12517791</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXjvFKgsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003;63:149–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_7">
              <CitationNumber>3.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Kokontsi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Takakura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Hay</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Liao</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>54</VolumeID>
                <FirstPage>1566</FirstPage>
                <LastPage>73</LastPage>
              </BibArticle>
              <BibUnstructured>Kokontsi J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994;54:1566–73.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_7">
              <CitationNumber>4.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Culig</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Hoffmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Erdel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IE</Initials>
                  <FamilyName>Eder</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hobisch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hittmair</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Bartsch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Utermann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Schneider</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Parczyk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Klocker</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>81</VolumeID>
                <FirstPage>242</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>10496349</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.bjc.6690684</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXmsFyitrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, et al. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999;81:242–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_7">
              <CitationNumber>5.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hobisch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IE</Initials>
                  <FamilyName>Eder</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Putz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Horninger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Bartsch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Klocker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Culig</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>58</VolumeID>
                <FirstPage>4640</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>9788616</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmslWrsLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998;58:4640–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_7">
              <CitationNumber>6.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MD</Initials>
                  <FamilyName>Sadar</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Gleave</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>60</VolumeID>
                <FirstPage>5825</FirstPage>
                <LastPage>31</LastPage>
                <Occurrence Type="PID">
                  <Handle>11059779</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXnvVSnt7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sadar MD, Gleave ME. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res 2000;60:5825–31.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_7">
              <CitationNumber>7.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SY</Initials>
                  <FamilyName>Tsai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Tsai</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>4511</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>9377562</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXmslKqt7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lu S, Tsai SY, Tsai MJ. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 1997;57:4511–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_7">
              <CitationNumber>8.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Yan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Erdem</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Cai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Ayala</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Ittmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LY</Initials>
                  <FamilyName>Yu-Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SY</Initials>
                  <FamilyName>Tsai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Tsai</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>68</VolumeID>
                <FirstPage>5460</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>18593949</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-08-0955</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXnvFyjuro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yan J, Erdem H, Li R, Cai Y, Ayala G, Ittmann M, et al. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res 2008;68:5460–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_7">
              <CitationNumber>9.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Comuzzi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Lambrinidis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Rogatsch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Godoy-Tundidor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Knezevic</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Krhen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Marekovic</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Bartsch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hobisch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Culig</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced receptor function</ArticleTitle>
                <JournalTitle>Am J Pathol</JournalTitle>
                <VolumeID>162</VolumeID>
                <FirstPage>233</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>12507906</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0002-9440(10)63814-X</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXlsF2jsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, et al. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced receptor function. Am J Pathol 2003;162:233–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_7">
              <CitationNumber>10.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Debes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Comuzzi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LJ</Initials>
                  <FamilyName>Schmidt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Dehm</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Culig</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>65</VolumeID>
                <FirstPage>5965</FirstPage>
                <LastPage>73</LastPage>
                <Occurrence Type="PID">
                  <Handle>15994976</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-04-2837</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXlslOqt7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Debes JD, Comuzzi B, Schmidt LJ, Dehm SM, Culig Z, Tindall DJ. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 2005;65:5965–73.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_7">
              <CitationNumber>11.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Steers</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">5alpha-reductase activity in the prostate</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>58</VolumeID>
                <FirstPage>17</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>11750244</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(01)01299-7</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD38%2FkvVagtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Steers WD. 5alpha-reductase activity in the prostate. Urology 2001;58:17–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_7">
              <CitationNumber>12.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LQ</Initials>
                  <FamilyName>Cai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YS</Initials>
                  <FamilyName>Zhu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MD</Initials>
                  <FamilyName>Katz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Herrera</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Baez</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Fillo-Ricart</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CH</Initials>
                  <FamilyName>Shackleton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Imperato-McGindley</FamilyName>
                </BibAuthorName>
                <Year>199</Year>
                <ArticleTitle Language="En">5-alpha-reductase-2 gene mutations in the Dominican republic</ArticleTitle>
                <JournalTitle>Clin Endocrinol Metab</JournalTitle>
                <VolumeID>81</VolumeID>
                <FirstPage>1730</FirstPage>
                <LastPage>5</LastPage>
              </BibArticle>
              <BibUnstructured>Cai LQ, Zhu YS, Katz MD, Herrera C, Baez J, de Fillo-Ricart M, et al. 5-alpha-reductase-2 gene mutations in the Dominican republic. Clin Endocrinol Metab. 199;81:1730–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_7">
              <CitationNumber>13.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IB</Initials>
                  <FamilyName>Joseph</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JB</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SR</Initials>
                  <FamilyName>Denmeade</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>Isaacs</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>2507</FirstPage>
                <LastPage>11</LastPage>
                <Occurrence Type="PID">
                  <Handle>9815654</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXisFSjsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997;3:2507–11.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_7">
              <CitationNumber>14.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MP</Initials>
                  <FamilyName>O’Leary</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Roehrborn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Andriole</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Nickel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Boyle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Höfner</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>92</VolumeID>
                <FirstPage>262</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>12887480</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1046/j.1464-410X.2003.04310.x</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>O’Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int 2003;92:262–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_7">
              <CitationNumber>15.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Titus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Gregory</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OH</Initials>
                  <FamilyName>Ford</FamilyName>
                  <Suffix>3rd</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Schell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Maygarden</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Mohler</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>4365</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>15958619</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-04-0738</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXltFelu7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Titus MA, Gregory CW, Ford 3rd OH, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005;11:4365–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_7">
              <CitationNumber>16.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Titus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Schell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FB</Initials>
                  <FamilyName>Lih</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KB</Initials>
                  <FamilyName>Tomer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Mohler</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>4653</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>16000557</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-05-0525</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXlvVGhtrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_7">
              <CitationNumber>17.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LN</Initials>
                  <FamilyName>Thomas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RC</Initials>
                  <FamilyName>Douglas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CB</Initials>
                  <FamilyName>Lazier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Gupta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RW</Initials>
                  <FamilyName>Norman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PR</Initials>
                  <FamilyName>Murphy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Rittmaster</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CK</Initials>
                  <FamilyName>Too</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>179</VolumeID>
                <FirstPage>147</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>17997435</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2007.08.155</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Thomas LN, Douglas RC, Lazier CB, Gupta R, Norman RW, Murphy PR, et al. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 2008;179:147–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_7">
              <CitationNumber>18.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FK</Initials>
                  <FamilyName>Habib</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Bayne</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Bollina</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Grigor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Chapman</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>9</VolumeID>
                <FirstPage>1815</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12738739</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXjsFeitLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Habib FK, Ross M, Bayne CW, Bollina P, Grigor K, Chapman K. The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis. Clin Cancer Res 2003;9:1815–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_7">
              <CitationNumber>19.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hobisch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Culig</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Radmayr</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Bartsch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Klocker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hittmair</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Distant metastases from prostatic carcinoma express androgen receptor protein</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>55</VolumeID>
                <FirstPage>3068</FirstPage>
                <LastPage>72</LastPage>
                <Occurrence Type="PID">
                  <Handle>7541709</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXmvVyit70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995;55:3068–72.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_7">
              <CitationNumber>20.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Kinoshita</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Shi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Sandefur</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LF</Initials>
                  <FamilyName>Meisner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Choon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CR</Initials>
                  <FamilyName>Reznikoff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GS</Initials>
                  <FamilyName>Bova</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Friedl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DF</Initials>
                  <FamilyName>Jarrard</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>60</VolumeID>
                <FirstPage>3623</FirstPage>
                <LastPage>30</LastPage>
                <Occurrence Type="PID">
                  <Handle>10910077</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXkvFChsbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, Choon A, et al. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res 2000;60:3623–30.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_7">
              <CitationNumber>21.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Makridakis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Akalu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Reichardt</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue</ArticleTitle>
                <JournalTitle>Oncogene</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>7399</FirstPage>
                <LastPage>405</LastPage>
                <Occurrence Type="PID">
                  <Handle>15326487</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.onc.1207922</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXnslelt7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Makridakis N, Akalu A, Reichardt JK. Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue. Oncogene 2004;23:7399–405.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_7">
              <CitationNumber>22.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Makridakis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RK</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Pike</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LE</Initials>
                  <FamilyName>Crocitto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LN</Initials>
                  <FamilyName>Kolonel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Pearce</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BE</Initials>
                  <FamilyName>Henderson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Reichardt</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Association of mis-sense subtitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles</ArticleTitle>
                <JournalTitle>USA Lancet</JournalTitle>
                <VolumeID>354</VolumeID>
                <FirstPage>975</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0140-6736(98)11282-5</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXmslWks7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, et al. Association of mis-sense subtitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles. USA Lancet 1999;354:975–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_7">
              <CitationNumber>23.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Festuccia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GL</Initials>
                  <FamilyName>Gravina</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Muzi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Pomante</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Angelucci</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Vicentini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Bologna</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>180</VolumeID>
                <FirstPage>367</FirstPage>
                <LastPage>72</LastPage>
                <Occurrence Type="PID">
                  <Handle>18499161</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2008.02.036</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXosVGjtLg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Festuccia C, Gravina GL, Muzi P, Pomante R, Angelucci A, Vicentini C, et al. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386. J Urol 2008;180:367–72.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_7">
              <CitationNumber>24.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Xu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Dalrymple</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Becker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SR</Initials>
                  <FamilyName>Denmeade</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>Isaacs</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>4072</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16818707</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-06-0184</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XmsVaksr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 2006;12:4072–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_7">
              <CitationNumber>25.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LJ</Initials>
                  <FamilyName>Schmidt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Murillo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Gene expression in prostate cancer cells treated with the dual 5-alpha-reductase inhibitor dutasteride</ArticleTitle>
                <JournalTitle>J Androl</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>944</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>15477368</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtVaitbbO</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Schmidt LJ, Murillo H, Tindall DJ. Gene expression in prostate cancer cells treated with the dual 5-alpha-reductase inhibitor dutasteride. J Androl 2004;25:944–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_7">
              <CitationNumber>26.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SE</Initials>
                  <FamilyName>Eggener</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Stern</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PM</Initials>
                  <FamilyName>Jain</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Oram</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Ai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Cai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Roehl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Enhancement of intermittent androgen ablation by “off-cycle” maintenance with finasteride in LNCaP prostate cancer xenograft model</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>66</VolumeID>
                <FirstPage>495</FirstPage>
                <LastPage>502</LastPage>
                <Occurrence Type="PID">
                  <Handle>16372330</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20297</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XjslWgtLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Eggener SE, Stern JA, Jain PM, Oram S, Ai J, Cai X, et al. Enhancement of intermittent androgen ablation by “off-cycle” maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate 2006;66:495–502.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_7">
              <CitationNumber>27.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Tsukamoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Akaza</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Onozawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Shirai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Ideyama</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>82</VolumeID>
                <FirstPage>531</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>9452271</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/(SICI)1097-0142(19980201)82:3&lt;531::AID-CNCR15&gt;3.0.CO;2-2</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXpt1yrsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tsukamoto S, Akaza H, Onozawa M, Shirai T, Ideyama A. A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer 1998;82:531–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_7">
              <CitationNumber>28.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Presti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Fair</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Andriole</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>Sogani</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Seidmon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Ferguson</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>148</VolumeID>
                <FirstPage>1201</FirstPage>
                <Occurrence Type="PID">
                  <Handle>1383574</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Presti JC, Fair WR, Andriole G, Sogani PC, Seidmon EJ, Ferguson D. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 1992;148:1201.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_7">
              <CitationNumber>29.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Andriole</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Lieber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Soloway</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Schroeder</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Kadmon</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Treatment with finasteride following radical prostatectomy for prostate cancer</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>45</VolumeID>
                <FirstPage>491</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>7533461</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(99)80021-1</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2M7osFShtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Andriole G, Lieber M, Smith J, Soloway M, Schroeder F, Kadmon D. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995;45:491–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_7">
              <CitationNumber>30.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LG</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>XM</Initials>
                  <FamilyName>Liu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Kreis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Budman</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>714</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>9044850</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXht1yksL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wang LG, Liu XM, Kreis W, Budman DR. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res 1997;57:714–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_7">
              <CitationNumber>31.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>FK</Initials>
                  <FamilyName>Habib</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CK</Initials>
                  <FamilyName>Ho</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Lyons</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Chapman</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">
                  <Emphasis Type="Italic">Serenoa repens</Emphasis>(Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>114</VolumeID>
                <FirstPage>190</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>15543614</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/ijc.20701</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtFOlurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Habib FK, Ross M, Ho CK, Lyons V, Chapman K.<Emphasis Type="Italic">Serenoa repens</Emphasis>(Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer 2005;114:190–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_7">
              <CitationNumber>32.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Klotz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Saad</FamilyName>
                </BibAuthorName>
                <InstitutionalAuthorName>PCPT-MTOPS Consensus Panel</InstitutionalAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice</ArticleTitle>
                <JournalTitle>Can Urol Assoc J</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>17</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>18542756</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Klotz L, Saad F, PCPT-MTOPS Consensus Panel. PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice. Can Urol Assoc J 2007;1:17–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_7">
              <CitationNumber>33.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Lucia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JI</Initials>
                  <FamilyName>Epstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Goodman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AK</Initials>
                  <FamilyName>Darke</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VE</Initials>
                  <FamilyName>Reuter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Civantos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>Parnes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Lippman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FG</Initials>
                  <FamilyName>Rosa</FamilyName>
                  <Particle>La</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MW</Initials>
                  <FamilyName>Kattan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ED</Initials>
                  <FamilyName>Crawford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LG</Initials>
                  <FamilyName>Ford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Coltman</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IM</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>99</VolumeID>
                <FirstPage>1375</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>17848673</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djm117</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1aiu7vO</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_7">
              <CitationNumber>34.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Goodman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Crowley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Carlin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Ryan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Coltman</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LG</Initials>
                  <FamilyName>Ford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IM</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Implementation of the prostate cancer prevention trial control</ArticleTitle>
                <JournalTitle>Clin Trials</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>203</FirstPage>
                <LastPage>22</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.cct.2003.11.007</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Goodman PJ, Tangen CM, Crowley JJ, Carlin SM, Ryan A, Coltman Jr CA, et al. Implementation of the prostate cancer prevention trial control. Clin Trials 2004;25:203–22.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_7">
              <CitationNumber>35.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LG</Initials>
                  <FamilyName>Gommella</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Chemoprevention using dutasteride: the REDUCE trial</ArticleTitle>
                <JournalTitle>Curr Opin Urol</JournalTitle>
                <VolumeID>15</VolumeID>
                <FirstPage>29</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00042307-200501000-00007</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gommella LG. Chemoprevention using dutasteride: the REDUCE trial. Curr Opin Urol 2005;15:29–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_7">
              <CitationNumber>36.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>McConnell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Bruskewitz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Walsh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Andriole</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Lieber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>Holtgrewe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Albertsen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CG</Initials>
                  <FamilyName>Roehrborn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Nickel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DZ</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Taylor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Waldstreicher</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>338</VolumeID>
                <FirstPage>557</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>9475762</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM199802263380901</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXhsF2ktr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med 1998;338:557–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_7">
              <CitationNumber>37.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GS</Initials>
                  <FamilyName>Merrick</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WM</Initials>
                  <FamilyName>Butler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KE</Initials>
                  <FamilyName>Wallner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RW</Initials>
                  <FamilyName>Galbreath</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ZA</Initials>
                  <FamilyName>Allen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Kurko</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>68</VolumeID>
                <FirstPage>116</FirstPage>
                <LastPage>20</LastPage>
                <Occurrence Type="PID">
                  <Handle>16844453</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urology.2006.01.061</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Kurko B. Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy. Urology 2006;68:116–20.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_7">
              <CitationNumber>38.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Rubin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Kantoff</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Effect of finasteride on risk of prostate cancer: how little we really know</ArticleTitle>
                <JournalTitle>J Cell Biochem</JournalTitle>
                <VolumeID>91</VolumeID>
                <FirstPage>478</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>14755678</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/jcb.10787</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhsVWjsrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rubin MA, Kantoff PW. Effect of finasteride on risk of prostate cancer: how little we really know. J Cell Biochem 2004;91:478–82.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
